留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

原发性肾上腺淋巴瘤的诊断与临床处理

邓建华 李汉忠

邓建华, 李汉忠. 原发性肾上腺淋巴瘤的诊断与临床处理[J]. 协和医学杂志, 2020, 11(1): 91-95. doi: 10.3969/j.issn.1674-9081.20170164
引用本文: 邓建华, 李汉忠. 原发性肾上腺淋巴瘤的诊断与临床处理[J]. 协和医学杂志, 2020, 11(1): 91-95. doi: 10.3969/j.issn.1674-9081.20170164
Jian-hua DENG, Han-zhong LI. Diagnosis and Clinical Treatment of Primary Adrenal Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 91-95. doi: 10.3969/j.issn.1674-9081.20170164
Citation: Jian-hua DENG, Han-zhong LI. Diagnosis and Clinical Treatment of Primary Adrenal Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 91-95. doi: 10.3969/j.issn.1674-9081.20170164

原发性肾上腺淋巴瘤的诊断与临床处理

doi: 10.3969/j.issn.1674-9081.20170164
基金项目: 

中国医学科学院医学与健康创新工程 2017-I2M-1-001

详细信息
    通讯作者:

    李汉忠 电话:010-69156035, E-mail:lihzhpumch@163.com

  • 中图分类号: R736

Diagnosis and Clinical Treatment of Primary Adrenal Lymphoma

More Information
  • 摘要: 原发性肾上腺淋巴瘤(primary adrenal lymphoma, PAL)临床表现不典型, 多数患者存在局部疼痛或全身发热、消瘦症状, 在双侧受累患者中肾上腺皮质功能不全很常见, 但仅少数患者进行全面系统的检查。正电子发射断层扫描/计算机体层成像是定性定位诊断这类肾上腺肿瘤的有效手段, 磁共振成像用来区别肾上腺淋巴瘤与皮质癌尚有待更多研究证实。对于PAL的治疗尚需进一步研究, 以对此类患者制定最佳的诊疗方案。目前, 尚不清楚利妥昔单克隆抗体联合CHOP方案(环磷酰胺+阿霉素+长春新碱+强的松)治疗高危侵袭性PAL患者是否可提高患者完全反应率。病变早期, 尤其是在肾上腺皮质功能不全出现之前诊断PAL, 有助于减少患者的发病率和死亡率。
    利益冲突  无
  • [1] Rashidi A, Fisher SI. Primary adrenal lymphoma:a systematic review[J]. Ann Hematol, 2013, 92:1583-1593. doi:  10.1007/s00277-013-1812-3
    [2] Kumar R, Xiu Y, Mavi A, et al. FDG-PET imaging in primary bilateral adrenal lymphoma:a case report and review of the literature[J]. Clin Nucl Med, 2016, 30:222-230. https://www.ncbi.nlm.nih.gov/pubmed/15764875
    [3] Kasaliwal R, Goroshi M, Khadilkar K, et al. Primary Adrenal Lymphoma:A Single-center Experience[J].Endocr Pract, 2015, 21:719-724. doi:  10.4158/EP14471.OR
    [4] Martínez-Esteve A, García-Gómez FJ, Madrigal-Toscano MD, et al. Primary bilateral diffuse large B-cell lymphoma of the adrenals[J]. Br J Haematol, 2015, 170:3. doi:  10.1111/bjh.13466
    [5] Raoofziaee M, Yarmohamadi A, Ahmadnia H.Primary bilateral non-Hodgkin's lymphoma of the adrenal gland[J].Indian J Urol, 2018, 34:300-302. doi:  10.4103/iju.IJU_113_18
    [6] Ohkura Y, Shindoh J, Haruta S, et al. Primary Adrenal Lymphoma Possibly Associated With Epstein-Barr Virus Reactivation Due to Immunosuppression Under Methotrexate Therapy[J]. Medicine, 2015, 94:e1270. doi:  10.1097/MD.0000000000001270
    [7] Mozos A, Ye H, Chuang WY, et al. Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis[J]. Mod Pathol, 2009, 22:1210-1217. doi:  10.1038/modpathol.2009.87
    [8] Grigg AP, Connors JM. Primary adrenal lymphoma[J]. Clin Lymphoma, 2016, 4:154-160. https://www.ncbi.nlm.nih.gov/pubmed/12769357
    [9] Padhi S, Sahoo J. Primary adrenal non Hodgkin lymphoma:changing trends[J]. Turk J Gastroenterol, 2015, 26:85-86. doi:  10.5152/tjg.2015.4882
    [10] Erçolak V, Kara O, Günaldi M, et al. Bilateral primary adrenal non-hodgkin lymphoma[J]. Turk J Haematol, 2014, 31:205-206. doi:  10.4274/tjh.2013.0195
    [11] Robertus JL, Harms G, Blokzijl T, et al. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma[J]. Mod Pathol, 2009, 22:547-555. doi:  10.1038/modpathol.2009.10
    [12] Nakatsuka S, Hongyo T, Syaifudin M, et al. Mutations of p53, c-kit, K-ras, and beta-catenin gene in non-Hodgkin's lymphoma of adrenal gland[J]. Jpn J Cancer Res, 2002, 93:267-274. doi:  10.1111/j.1349-7006.2002.tb02168.x
    [13] Ide M, Fukushima N, Hisatomi T, et al. Non-germinal cell phenotype and Bcl-2 expression in primary adrenal diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2007, 48:2244-2246. doi:  10.1080/10428190701636450
    [14] Hong J, Park S, Park J, et al. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy[J]. Leuk Lymphoma, 2011, 52:1904-1912. doi:  10.3109/10428194.2011.588761
    [15] Hans CP, Weisenburger DD, Greiner TC, et al. Confirma-tion of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103:275-282. doi:  10.1182/blood-2003-05-1545
    [16] Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy[J]. Clin Cancer Res, 2009, 15:5494-5502. doi:  10.1158/1078-0432.CCR-09-0113
    [17] Eyden B, Chakrabarty B, Hatimy U. Carcinoma versus cytokeratin-positive lymphoma:a case report emphasizing the diagnostic role of electron microscopy[J]. Ultrastruct Pathol, 2009, 33:33-38. doi:  10.1080/01913120802625830
    [18] Rashidi A, Bergeron CW, Fisher SI, et al. Primary adrenal de novo CD5-positive diffuse large B-cell lymphoma[J]. Ann Hematol, 2013, 92:1281-1282. doi:  10.1007/s00277-013-1690-8
    [19] Donner LR, Mott FE, Tafur I. Cytokeratin-positive, CD45-negative primary centroblastic lymphoma of the adrenal gland:a potential for a diagnostic pitfall[J]. Arch Pathol Lab Med, 2001, 125:1104-1106. https://www.ncbi.nlm.nih.gov/pubmed/11473470
    [20] Chen P, Jin L, Yang Y, et al. Bilateral primary adrenal diffuse large B cell lymphoma without adrenal insufficiency:A case report and review of the literature[J]. Mol Clin Oncol, 2017, 7:145-147. doi:  10.3892/mco.2017.1264
    [21] Chakrabarti I, Bhowmik S, Sinha MG, et al. Ultrasound-guided aspiration cytology of retroperitoneal masses with histopathological corroboration:A study of 71 cases[J]. J Cytol, 2014, 3115-3119.
    [22] Mehmood S, Jahan A, Loya A, et al. Onsite cytopathology evaluation and ancillary studies beneficial in EUS-FNA of pancreatic, mediastinal, intra-abdominal, and submucosal lesions[J]. Diagn Cytopathol, 2015, 43:278-286. doi:  10.1002/dc.23207
    [23] Guo AC, Cummings TJ, Dash RC. Lymphomas and high-grade astrocytomas:comparison of water diffusibility and histologic characteristics[J]. Radiology, 2002, 224:177-183. doi:  10.1148/radiol.2241010637
    [24] Kuritzkes B, Parikh M, Melamed J, et al. False-positive rate of positron emission tomography/computed tomography for presumed solitary metastatic adrenal disease in patients with known malignancy[J]. Ann Surg Oncol, 2015, 22:437-440. doi:  10.1245/s10434-014-4031-9
    [25] Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diag-nostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies-a multicenter experience[J]. Hell J Nucl Med, 2015, 18:97-102.
    [26] López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma:clinical and biological characteriza-tion and outcome according to the nodal or extranodal primary origin[J]. J Clin Oncol, 2005, 23:2797-2804. doi:  10.1200/JCO.2005.07.155
    [27] Abe R, Ogawa K, Maruyama Y, et al. Spontaneous regression of diffuse large B-cell lymphoma harbouring Epstein-Barr virus:a case report and review of the literature[J]. J Clin Exp Hematop, 2007, 47:23-26. doi:  10.3960/jslrt.47.23
    [28] Marković O, Marisavljević D, Jelić S, et al. Double-hit primary unilateral adrenal lymphoma with good outcome[J]. Vojnosanit Pregl, 2014, 71:689-692. doi:  10.2298/VSP1407689M
    [29] Kim YR, Kim JS, Min YH, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)[J]. J Hematol Oncol, 2012, 5:49. doi:  10.1186/1756-8722-5-49
    [30] Acker SN, Bruny JL, Garrington TP, et al. Minimally invasive surgical techniques are safe in the diagnosis and treatment of pediatric malignancies[J]. Surg Endosc, 2015, 29:1203-1208. doi:  10.1007/s00464-014-3795-0
    [31] Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346:235-242. doi:  10.1056/NEJMoa011795
    [32] Hiemcke-Jiwa LS, Leguit RJ, Radersma-van Loon JH, et al.Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement[J]. Leuk Lymphoma, 2017, 29:1-4. http://europepmc.org/abstract/MED/28849690
    [33] Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)[J]. Ann Oncol, 2007, 18:149-157. doi:  10.1093/annonc/mdl327
    [34] Ferreri AJ, Assanelli A, Crocchiolo R, et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas:incidence, risk factors and therapeutic options[J]. Hematol Oncol, 2016, 27:61-70. doi:  10.1002/hon.881
  • 加载中
计量
  • 文章访问数:  469
  • HTML全文浏览量:  35
  • PDF下载量:  140
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-05-18
  • 刊出日期:  2020-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!